FDA Accelerates Review of Psychedelics for Mental Health
The FDA is set to expedite the review process for three psychedelics as potential treatments for mental health issues, influenced by changing political attitudes.
Editorial Staff
1 min read
Updated 15 days ago
The FDA has announced plans to accelerate the review of three psychedelic substances that may serve as treatments for mental health conditions.
This decision is reportedly influenced by a shift in political perspectives, particularly with former President Trump's recent support for psychedelics and cannabis.
As the GOP's stance on mind-altering substances evolves, the implications for mental health treatment and regulatory practices could be significant.